Zarxio lessons

Sandoz is blazing a trail for commercialization of biosimilars in the U.S. with its application to market Zarxio, a biosimilar version of Amgen Inc.'s Neupogen filgrastim. The Novartis AG unit is using its first-mover position to force FDA and the courts to make decisions that will shape the economic and regulatory landscape for biosimilars.

BioCentury recently spoke with Mark McCamish, global head of biopharmaceuticals and oncology injectables development at Sandoz...